Eicosanoid biosynthetic enzyme

Eicosanoid biosynthetic enzymes include a series of enzymes such as phospholipase A2 (PLA2), cyclooxygenases (COX-1, COX-2), lipoxygenases (LOX), and cytochrome P450 enzymes (CYP) that convert membrane-bound polyunsaturated fatty acids (mainly arachidonic acid) into eicosanoids. These enzymes act sequentially and locally within tissues to generate diverse eicosanoids—prostaglandins, leukotrienes, thromboxanes, and related oxylipins—that regulate cellular processes including inflammation, immune cell recruitment, blood clotting, fever generation, vascular tone, and pain perception. Dysregulation of eicosanoid biosynthesis is central to the pathogenesis of a wide array of diseases, making these enzymes prime targets for therapy, particularly anti-inflammatory and anti-thrombotic drugs[1][3][4][5][6]. Note: "Eicosanoid biosynthetic enzymes" is a collective term, not a specific protein or target; for structured drug-target databases, mapping to individual enzymes (e.g., Cyclooxygenase-2) is recommended for precision.

Inhibition of cyclooxygenase enzyme (block prostaglandin/thromboxane synthesis); Inhibition of lipoxygenase enzyme (reduce leukotriene synthesis); Inhibition of phospholipase A2 (prevent eicosanoid precursor release); Modulation of eicosanoid receptor activity (antagonism/agonism)